Delving into the Latest Updates on The First Affiliated Hospital, Zhejiang University Sch of Med with Synapse

Overview

Tags

Neoplasms

Hemic and Lymphatic Diseases

Immune System Diseases

CAR-T

Small molecule drug

Antibody drug conjugate (ADC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Hemic and Lymphatic Diseases	3
Immune System Diseases	2
Infectious Diseases	1

Top 5 Drug Type	Count

CAR-T	2
Small molecule drug	1
Antibody drug conjugate (ADC)	1
Universal CAR-T	1
Bispecific antibody	1

Top 5 Target	Count

CK1ε x PI3Kδ	1
DNA x c-Met	1
CA2(Carbonic anhydrase II)	1
BCMA x CD19	1
CD19 x CD22	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

2

Preclinical

Phase 1

4

3

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

anti-CD19/BCMA CAR-T therapy (Zhejiang University) ( BCMA x CD19 )	Autoimmune Diseases More	Phase 1
allogeneic CAR-T (Zhejiang Universtiy) ( CD19 )	Hematologic Diseases More	Phase 1
CD19/CD22 CAR-T (Zhejiang Universtiy) ( CD19 x CD22 )	Hematologic Neoplasms More	Phase 1
HZ-H08905 ( CK1ε x PI3Kδ )	Hematologic Neoplasms More	Phase 1
hu7v3-Fc ( CLDN18.2 )	Neoplasms More	Preclinical